tobramycin + tobramycin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Infections
Conditions
Pseudomonas Infections
Trial Timeline
Feb 1, 2008 → Aug 1, 2009
NCT ID
NCT00634192About tobramycin + tobramycin
tobramycin + tobramycin is a phase 3 stage product being developed by Novartis for Pseudomonas Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00634192. Target conditions include Pseudomonas Infections.
What happened to similar drugs?
1 of 4 similar drugs in Pseudomonas Infections were approved
Approved (1) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00634192 | Phase 3 | Completed |
Competing Products
8 competing products in Pseudomonas Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 42 |
| Tobramycin inhalation powder | Novartis | Phase 3 | 40 |
| TIS or TIP | Novartis | Approved | 35 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 32 |
| Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Phase 1 | 26 |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Insmed | Phase 3 | 37 |
| TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® | Viatris | Pre-clinical | 23 |
| IC43 + Placebo | Valneva SE | Phase 2/3 | 32 |